Enlarged waist combined with elevated triglycerides (hypertriglyceridemic waist phenotype) and HDL-cholesterol in patients with heart failure
Keywords:
Cholesterol, HDL, Heart failure, Hypertriglyceridemia, Waist circumference, Cardiovascular diseasesAbstract
CONTEXT AND OBJECTIVE: The association of serum triglycerides plus waist circumference seems to be a good marker of cardiovascular risk and has been named the hypertriglyceridemic waist” phenotype. The aim of our study was to investigate the association between the hypertriglyceridemic waist phenotype and HDL-cholesterol among patients with heart failure. DESIGN AND SETTING: Cross-sectional study in a tertiary-level hospital in southern Brazil. METHODS: We included patients with heart failure aged > 40 years. Anthropometric assessment (weight, height, waist and hip circumferences) was performed; body mass index (BMI) and waist-hip ratio were calculated and lipid measurements (serum total cholesterol, LDL-cholesterol, HDL-cholesterol and triglycerides) were collected. In men and women, respectively, waist circumference ≥ 94 cm and ≥ 80 cm, and triglycerides ≥ 150 mg/dl were considered abnormal and were used to identify the hypertriglyceridemic waist phenotype. Analyses of covariance were used to evaluate possible associations between levels of HDL-cholesterol and the hypertriglyceridemic waist phenotype, according to sex. RESULTS: 112 participants were included, of whom 62.5% were men. The mean age was 61.8 ± 12.3 years and the mean ejection fraction was 40.1 ± 14.7%. Men and woman presented mean HDL-cholesterol of 40.5 ± 14.6 and 40.9 ± 12.7 mg/dl, respectively. The prevalence of the hypertriglyceridemic waist phenotype was 25%. There was a significant difference in mean HDL-cholesterol between men with and without the hypertriglyceridemic waist phenotype (32.8 ± 14.2 versus 42.1 ± 13.7 mg/dl respectively; P = 0.04), even after adjustment for age, body mass index, type 2 diabetes mellitus, use of statins and heart failure etiology. CONCLUSIONS: The hypertriglyceridemic waist phenotype is significantly associated with lower HDL-cholesterol levels in men with heart failure.
Downloads
References
McMurray JJ, Pfeffer MA. Heart failure. Lancet. 2005;365(9474):1877-89.
Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;62(16):e147-239.
Sharma A, Lavie CJ, Borer JS, et al. Meta-analysis of the relation of body mass index to all-cause and cardiovascular mortality and hospitalization in patients with chronic heart failure. Am J Cardiol. 201;115(10):1428-34.
Vogel P, Stein A, Marcadenti A. Visceral adiposity index and prognosis among patients with ischemic heart failure. Sao Paulo Med J. 2016;134(3):211-8.
Lamarche B, Tchernof A, Mauriège P, et al. Fasting insulin and apolipoprotein B levels and low-density lipoprotein particle size as risk factors for ischemic heart disease. JAMA. 1998;279(24):1955-61.
Blackburn P, Lemieux I, Lamarche B, et al. Type 2 diabetes without the atherogenic metabolic triad does not predict angiographically assessed coronary artery disease in women. Diabetes Care. 2008;31(1):170-2.
Kahn HS, Valdez R. Metabolic risks identified by the combination of enlarged waist and elevated triacylglycerol concentration. Am J Clin Nutr. 2003;78(5):928-34.
Lemiux I, Pascot A, Couillard C, et al. Hypertriglyceridemic waist: A marker of the atherogenic metabolic triad (hyperinsulinemia; hyperapolipoprotein B; small, dense LDL) in men? Circulation. 2000;102(2):179-84.
Hobkirk JP, King RF, Gately P, et al. The predictive ability of triglycerides and waist (hypertriglyceridemic waist) in assessing metabolic triad change in obese children and adolescents. Metab Syndr Relat Disord. 2013;11(5):336-42.
Sam S, Haffner S, Davidson MH, et al. Hypertriglyceridemic waist phenotype predicts increased visceral fat in subjects with type 2 diabetes. Diabetes Care. 2009;32(10):1916-20. 11. Gasevic D, Carlsson AC, Lesser IA, Mancini GJ, Lear SA. The association between“hypertriglyceridemic waist” and sub-clinical atherosclerosis in a multiethnic population: a cross-sectional study. Lipids Health Dis. 2014;13:38.
Gomez-Huelgas R, Bernal-López MR, Villalobos A, et al. Hypertriglyceridemic waist: an alternative to the metabolic syndrome? Results of the IMAP Study (multidisciplinary intervention in primary care). Int J Obes (Lond). 2011;35(2):292-9.
Solati M, Ghanbarian A, Rahmani M, et al. Cardiovascular risk factors in males with hypertriglycemic waist (Tehran Lipid and Glucose Study). Int J Obes Relat Metab Disord. 2004;28(5):706-9.
Cabral NAL, Ribeiro VS, França AKTC, et al. Cintura hipertrigliceridêmica e risco cardiometabólico em mulheres hipertensas [Hypertriglyceridemic waist and cardiometabolic risk in hypertensive women]. Rev Assoc Med Bras (1992). 2012;58(5):568-73.
Radenković SP, Kocić RD, Pešić MM, et al. The hypertriglyceridemic waist phenotype and metabolic syndrome by differing criteria in type 2 diabetic patients and their relation to lipids and blood glucose control. Endokrynol Pol. 2011;62(4):316-23.
Yang RF, Lin Z, Liu XY, Zhang G. A clinical study of patients with coronary heart disease complicated with hypertriglyceridemic waist phenotype. Cell Biochem Biophys. 2014;70(1):289-93.
Tankó LB, Bagger YZ, Qin G, et al. Enlarged waist combined with elevated triglycerides is a strong predictor of accelerated atherogenesis and related cardiovascular mortality in postmenopausal women. Circulation. 2005;111(15):1883-90.
Arsenault BJ, Barter P, DeMicco DA, et al. Prediction of cardiovascular events in statin-treated stable coronary patients by lipid and nonlipid biomarkers. J Am Coll Cardiol. 2011;57(1):63-9.
Yunke Z, Guoping L, Zhenyue C. Triglyceride-to-HDL cholesterol ratio. Predictive value for CHD severity and new-onset heart failure. Herz. 2014;39(1):105-10.
Blackburn P, Lemieux I, Lamarche B, et al. Angiographically-assessed coronary artery disease associates with HDL particle size in women. Atherosclerosis. 2012;223(2):359-64.
Sakatani T, Shirayama T, Suzaki Y, et al. The association between cholesterol and mortality in heart failure. Comparison between patients with and without coronary artery disease. Int Heart J. 2005;46(4):619-29.
Karadag MK, Akbulut M. Low HDL levels as the most common metabolic syndrome risk factor in heart failure. Int Heart J. 2009;50(5):571-80.
Zhe X, Bai Y, Cheng Y, et al. Hypertriglyceridemic waist is associated with increased carotid atherosclerosis in chronic kidney disease patients. Nephron Clin Pract. 2012;122(3-4):146-52.
Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013;128(16):1810-52.
Vigilância alimentar e nutricional - Sisvan: orientações básicas para a coleta, processamento, análise de dados e informação em serviços de saúde. Brasília: Ministério da Saúde; 2004. 26. World Health Organization. Division of Noncommunicable Diseases. Programme of Nutrition Family and Reproductive Health. Obesity: preventing and managing the global epidemic: report of a WHO consultation on obesity. Geneva: World Health Organization; 1998.
Brandão AA, Rodrigues CIS, Consolim-Colombo F, et al. VI Diretrizes Brasileiras de Hipertensão. Arq Bras Cardiol. 2010;95(1 supl. 1):1-51.
Sposito AC, Caramelli B, Fonseca FAH, et al. IV Diretriz Brasileira sobre Dislipidemias e Prevenção da Aterosclerose: Departamento de Aterosclerose da Sociedade Brasileira de Cardiologia. Arq Bras Cardiol. 2007;88 (supl 1):2-19.
Associação Brasileira para o Estudo da Obesidade e da Síndrome Metabólica. Diretrizes brasileiras de obesidade 2009/2010. 3a ed. Itapevi: AC Farmacêutica; 2009. Available from: http://www.abeso.org.br/pdf/diretrizes_brasileiras_obesidade_2009_2010_1.pdf. Accessed in 2016 (Nov 17).
American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2014;37 Suppl. 1:81-90.
Haack RL, Horta BL, Gicante DP, et al. Cintura hipertrigliceridêmica em adultos jovens no Sul do Brasil [The hypertriglyceridemic waist phenotype in young adults from the Southern Region of Brazil]. Cad Saúde Pública. 2013;29(5):999-1007.
Lemieux S, Prud’homme D, Bouchard C, Tremblay A, Després JP. Sex differences in the relation of visceral adipose tissue accumulation to total body fatness. Am J Clin Nutr. 1993;58(4):463-7.
Després JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature. 2006;444(7121):881-7.
Fülster S, Tacke M, Sandek A, et al. Muscle wasting in patients with chronic heart failure: results from the studies investigating co-morbidities aggravating heart failure (SICA-HF). Eur Heart J. 2013;34(7):512-9.
Okoshi MP, Romeiro FG, Paiva SAR, Okoshi K. Caquexia associada à insuficiência cardíaca [Heart failure-induced cachexia]. Arq Bras Cardiol. 2013;100(5):476-82.
Eguchi K, Manabe I. Toll-like receptor, lipotoxicity and chronic inflammation: the pathological link between obesity and cardiometabolic disease. J Atheroscler Thromb. 2014;21(7):629-39.
De Oliveira E Silva ER, Foster D, McGee Harper M, et al. Alcohol consumption raises HDL cholesterol levels by increasing the transport rate of apolipoproteins A-I and A-II. Circulation. 2000;102(19):2347-52.
Miura S, Saku K. Effects of statin and lipoprotein metabolism in heart failure. J Cardiol. 2010;55(3):287-90.
Wedel H, McMurray JJ, Lindberg M, et al. Predictors of fatal and non- fatal outcomes in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): incremental value of apolipoprotein A-I, high- sensitivity C-reactive peptide and N-terminal pro B-type natriuretic peptide. Eur Heart Fail. 2009;11(3):281-91.
Després JP. Cardiovascular disease under the influence of excess visceral fat. Crit Pathw Cardiol. 2007;6(2):51-9.
Blaak E. Gender differences in fat metabolism. Curr Opin Clin Nutr Metab Care. 2001;4(6):499-502.
Barter PJ, Baker PW, Rye KA. Effect of high-density lipoproteins on the expression of adhesion molecules in endothelial cells. Curr Opin Lipidol. 2002;13(3):285-8
